U.S. equity markets continued their robust performance on Monday, September 22, 2025, with major indexes extending their record-setting rally. Despite an early morning dip attributed to profit-taking and concerns over a potential government shutdown, afternoon trading saw a strong recovery, buoyed by optimistic investor sentiment following last week's Federal Reserve interest rate cut and significant corporate news in the technology and pharmaceutical sectors.Current Market Indexes and Afternoon ActivityThe ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Key Points Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE), the one-time COVID vaccine hero turned Ozempic craze zero, is marching higher Monday after announcing it will try to recover from its danuglipron setback by buying another drug company with weight loss dreams. As of 12:25 p.m. ET, Pfizer st ...

Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed to buy Metsera for $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met, it said Monday, with a total potential value of $7.3 billion. The deal represents a 43% premium to Metsera's closing share price on Friday. Bloomberg's Sam Fazeli repo ...

Pfizer has acquired Metsera for $4.9bn, as the drugmaker targets longer-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) to cement market share in the burgeoning weight loss treatment sector. Pfizer has agreed to buy all of Metsera’s shares for a price of $47.50 each, representing a 43% premium to Metsera’s closing share price of $33.32 on 19 September. The deal, forecast to close in Q4 2025, also includes potential additional payments of up to $22.50 per share in cash tied to three specific c ...

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE). Background: On September 21, 2025, Metsera and Pfizer entered into a definitive merger agreement. Under the terms of the agreement, holders of Metsera’s common stock will receive $47.50 per share in cash. In a ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Pfizer Inc. (NYSE: PFE ) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR ...

收购事件与市场反应 - 辉瑞公司将以高达73亿美元的价格收购减肥药公司Metsera [1] - 受收购消息影响 辉瑞股价上涨2.6%至24.65美元 有望创下自7月以来最大单日涨幅 [1] - 该股在过去12个月内下跌了16.5% 近期在25美元水平面临阻力 [1] 期权市场交易活动 - 看涨期权交易活跃 今日成交量达11.5万份 是日内平均成交量的四倍 看跌期权成交量仅为1.7万份 [2] - 最活跃的合约是10月25日到期和9月26日到期的24.50美元看涨期权 有新头寸正在这些合约上建立 [2] 期权市场情绪指标 - 50日看涨/看跌期权成交量比率为2.72 高于过去一年中82%的读数 表明期权交易员的看涨情绪远高于往常 [3] - 该股的Schaeffer波动率指数为23% 处于其年度范围的第五百分位 意味着期权交易员定价的波动预期较低 [4]

(Bloomberg) -- Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications.The US drugmaker agreed to buy Metsera for $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met, it said Monday, with a total potential value of $7.3 billion. The deal represents a 43% premium to Metsera’s closing share price on Friday. Also Read | TC ...